Huang CL, Huang NK, Shyue SK, Chern Y
a) Somatostatin b) Glucagon c) Ghrelin d) Cortisol Answer: b) Glucagon Typical onset of gastric emptying delay is: a) Within minutes b) Within hours c) After weeks d) No effect Answer: b) Within hours Semaglutide injection frequency is: a) Daily b) Weekly c) Monthly d) As-needed Answer: b) Weekly A rare but serious adverse effect to monitor is: a) Hypoglycemia b) Pancreatitis c) Hyperthyroidism d) Nephrolithiasis Answer: b) Pancreatitis It is contraindicated in patients with: a) Type 1 diabetes b) Medullary thyroid carcinoma c) Obesity d) Hypertension Answer: b) Medullary thyroid carcinoma Compared to exenatide, semaglutide yields: a) Less weight loss b) More weight loss c) Higher injection frequency d) Less HbAc reduction Answer: b) More weight loss Half-life of semaglutide is approximately: a) 24 hours b) 3 days c) 7 days d) 15 days Answer: c) 7 days Excretion involves: a) High renal elimination b) Only feces c) Metabolism and minimal excretion d) Biliary excretion Answer: c) Metabolism and minimal excretion An added cardiovascular benefit was shown in: a) SUSTAIN trials b) DPP4 studies c) RAAS inhibitor trials d) REM sleep studies Answer: a) SUSTAIN trials Weight loss percentage ranges from: a) 15% b) 510% c) 1017% d) 2025% Answer: c) 1017% A significant GI side effect is: a) Increased appetite b) Nausea c) Insomnia d) Hypertension Answer: b) Nausea Semaglutide metabolism involves: a) CYP3A4 b) Proteolysis c) Renal enzymes only d) Conjugation Answer: b) Proteolysis An advantage over liraglutide is: a) Lower efficacy b) Higher weight loss c) Daily dosing d) Less frequent injection Answer: d) Less frequent injection FAQs Does semaglutide cause weight loss in non-diabetic patients
Melatonin acts as a potent free radical scavenger and antioxidant in vitro, independently of the presence of the receptor (38, 67, 68) protecting lipids, protein and DNA from oxidative damage
IMPORTANT NOTICE: This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use
tirzepatide: +7.60 20.28 U/L
The most common cause is pernicious anemia, an auto-immune disorder that affects around one in every 10,000 people
